Sandbox:glomerular disease: Difference between revisions

Revision as of 13:03, 16 November 2016

Glomerular Disease	Physical Examination			Laboratory Studies								Management		Prognosis
Glomerular Disease	Blood Pressure	Edema	Other Physical Manifestations	Proteinuria	Lipiduria	Albumin	Serum Lipids	C3/C4	ANCA	Anti-GBM	Other Serologies	Initial Treatment	Maintenance Treatment	Prognosis
Diabetic Nephropathy
Minimal Change Disease					+++
Primary FSGS
Paraprotein Related Renal Disease
Granulomatosis with polyangitis									✔			PDN;INN	PDN;AZA
Alport syndrome
Goodpasture syndrome										✔		PDN; INN; PPH*
Eosinophilic granulomatosis with polyangiitis									✔		Eosinophilia	PDN*	Non severe: PDN; MTX, AZA, HU Severe: PDN; INN; AZA* or MTX*
Microscopic polyangiitis									✔

* AZA=Azathioprine; HU=Hydroxyurea; INN=Cyclophosphamide;

MTX=Methotrexate; PDN=Prednisone; PPH=Plasmapheresis

@@ Line 96: / Line 96: @@
 |
 |
-|
+|PDN*;INN*
-|
+|PDN*;AZA*
 |
 |-
@@ Line 128: / Line 128: @@
 |✔
 |
-|
+|PDN*; INN*; PPH*
 |
 |
@@ Line 143: / Line 143: @@
 |✔
 |
-|
+|Eosinophilia
-|
+|PDN*
-|
+|Non severe: PDN*; MTX*, AZA*, HU*
+Severe: PDN*; INN*; AZA* or MTX*
 |
 |-
@@ Line 196: / Line 198: @@
 |
 |}
+<nowiki>*</nowiki> AZA=Azathioprine; HU=Hydroxyurea; INN=Cyclophosphamide;
+MTX=Methotrexate; PDN=Prednisone; PPH=Plasmapheresis
 __NOTOC__